June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Effectiveness and Safety of Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment
Author Affiliations & Notes
  • Sebastiao Cronemberger
    Ophthalmology, Federal Univ of Minas Gerais, Belo Horizonte, Brazil
  • Juçara R Franca
    Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Alan Cezar Faria Araújo
    Ophthalmology, Federal Univ of Minas Gerais, Belo Horizonte, Brazil
  • Francine Rubião da Cunha
    Ophthalmology, Federal Univ of Minas Gerais, Belo Horizonte, Brazil
  • André Augusto Gomes Faraco
    Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil
  • Anderson Ferreira
    Morphology, Federal University of Minas Geris, Belo Horizonte, Brazil
  • Giselle Foureaux
    Morphology, Federal University of Minas Geris, Belo Horizonte, Brazil
  • Footnotes
    Commercial Relationships   Sebastiao Cronemberger, None; Juçara Franca, None; Alan Araújo, None; Francine Cunha, None; André Faraco, None; Anderson Ferreira, None; Giselle Foureaux, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2109. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sebastiao Cronemberger, Juçara R Franca, Alan Cezar Faria Araújo, Francine Rubião da Cunha, André Augusto Gomes Faraco, Anderson Ferreira, Giselle Foureaux; Effectiveness and Safety of Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2109.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :
Primary open-angle glaucoma (POAG) is initially treated with daily instillation of eye drops which are effective but may have adverse effects. Polymer systems of extended-release drugs may reduce these effects and improve adherence to treatment. We have developed an insert for sustained release of bimatoprost.
After, we assessed in patients with ocular hypertension (OH) or POAG the efficacy and safety of bimatoprost inserts in one eye compared to Lumigan™ eye drops in the contralateral eye.

Methods : All patients underwent the following exams by the same doctor: visual acuity measurement, slit lamp examination, Goldmann applanation tonometry, ultrasonic pachymetry, fundus examination and visual field testing. Inclusion criteria were both eyes with IOP>21mmHg without medication at 8:00 to 9:00 am; normal biomicroscopy; no antiglaucomatous or refractive surgery. Five normal patients with IOP≤14mmHg were also included. An insert of chitosan for prolonged release of bimatoprost was placed in the upper conjunctival fornix of the right eye (Fig. 1). In the left eye, patients instilled one drop of Lumigan™ daily at 9:00 pm. All exams were repeated weekly at 8:00 to 9:00 am for six weeks except the visual field. Anova two-way, Student test and paired-t test were used for statiscal analysis. The level of significancy was set at 0.05.

Results : No intolerance or discomfort with the insert was reported by the patients. In both eyes (insert and eye drop), the average IOP reduction was similar in the initial 3 weeks (insert: 31.2±10.3%, and eye drops: 34.8±10.1%). The percentage of IOP reduction at the end of the 3rd week was of 30% for insert and of 35% for eye drops (Fig. 2). A research conducted by CTIT/UFMG with participants demonstrated that 58% prefer insert; 25% prefer eye drops and 17% have no preference. Insert runs in 83.3% of patients and 58% of them would change the instillation of the eye drops to inserts. The reasons are practicality of the insert; forgetfulness (instilling eye drops) and higher price of eye drops.

Conclusions : The insert of bimatoprost reduced significantly the IOP, similarly to what happened with Lumigan™ eye drops, for 3 weeks. The use of insert can be an alternative to daily instillation of eye drops for the treatment of POAG or OH.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

Insert (upper fornix)

Insert (upper fornix)

 

% of IOP reduction at 3 weeks

% of IOP reduction at 3 weeks

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×